Biocept Company Profile (NASDAQ:BIOC)

About Biocept (NASDAQ:BIOC)

Biocept logoBiocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIOC
  • CUSIP: N/A
  • Web: www.biocept.com
Capitalization:
  • Market Cap: $33.87 million
  • Outstanding Shares: 22,280,000
Average Prices:
  • 50 Day Moving Avg: $1.72
  • 200 Day Moving Avg: $1.53
  • 52 Week Range: $0.74 - $3.39
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.17
  • P/E Growth: -0.0500
Sales & Book Value:
  • Annual Revenue: $3.22 million
  • Price / Sales: 10.52
  • Book Value: $0.04 per share
  • Price / Book: 38.00
Profitability:
  • EBIDTA: ($17,700,000.00)
  • Net Margins: -876.22%
  • Return on Equity: -764.73%
  • Return on Assets: -279.58%
Debt:
  • Debt-to-Equity Ratio: -0.47%
  • Current Ratio: 0.35%
  • Quick Ratio: 0.25%
Misc:
  • Average Volume: 930,371 shs.
  • Beta: 2.65
  • Short Ratio: 2.29
 

Frequently Asked Questions for Biocept (NASDAQ:BIOC)

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How were Biocept's earnings last quarter?

Biocept Inc (NASDAQ:BIOC) announced its earnings results on Tuesday, March, 7th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.07. The firm had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.26 million. Biocept had a negative return on equity of 764.73% and a negative net margin of 876.22%. View Biocept's Earnings History.

Where is Biocept's stock going? Where will Biocept's stock price be in 2017?

3 equities research analysts have issued 1-year price targets for Biocept's shares. Their predictions range from $2.00 to $3.00. On average, they expect Biocept's stock price to reach $2.50 in the next twelve months. View Analyst Ratings for Biocept.

Who are some of Biocept's key competitors?

Who owns Biocept stock?

Biocept's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.13%), WealthTrust Axiom LLC (0.63%) and Intellectus Partners LLC (0.57%). Company insiders that own Biocept stock include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Institutional Ownership Trends for Biocept.

Who bought Biocept stock? Who is buying Biocept stock?

Biocept's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., WealthTrust Axiom LLC and Intellectus Partners LLC. Company insiders that have bought Biocept stock in the last two years include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Insider Buying and Selling for Biocept.

How do I buy Biocept stock?

Shares of Biocept can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Biocept stock cost?

One share of Biocept stock can currently be purchased for approximately $1.52.

Analyst Ratings

Consensus Ratings for Biocept (NASDAQ:BIOC) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (64.47% upside)

Analysts' Ratings History for Biocept (NASDAQ:BIOC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/13/2017Roth CapitalReiterated RatingBuy$1.60 -> $3.00LowView Rating Details
11/10/2016Feltl & Co.UpgradeHold -> Buy$2.00N/AView Rating Details
8/31/2016Rodman & RenshawSet Price TargetBuy$2.50N/AView Rating Details
1/10/2016HC WainwrightReiterated RatingBuy$4.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Biocept (NASDAQ:BIOC)
Earnings by Quarter for Biocept (NASDAQ:BIOC)
Earnings History by Quarter for Biocept (NASDAQ:BIOC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017Q4 2016($0.34)($0.27)$1.26 million$1.29 millionViewListenView Earnings Details
11/9/2016Q316($0.57)($0.57)$0.76 million$1.05 millionViewListenView Earnings Details
8/2/2016Q216($0.22)($0.20)$0.37 million$0.66 millionViewN/AView Earnings Details
5/12/2016Q116($0.23)($0.25)$0.48 million$0.22 millionViewListenView Earnings Details
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.24)$0.78 million$0.17 millionViewN/AView Earnings Details
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details
5/12/2015Q115($0.61)($0.37)$0.30 million$0.15 millionViewListenView Earnings Details
3/9/2015Q414($0.88)($0.87)$0.30 million$0.08 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.82)($0.87)$0.40 million$0.01 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.67)($0.67)$0.10 million$0.02 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biocept (NASDAQ:BIOC)
2017 EPS Consensus Estimate: ($0.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.19)($0.21)
Q2 20172($0.21)($0.19)($0.20)
Q3 20172($0.21)($0.17)($0.19)
Q4 20172($0.20)($0.18)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biocept (NASDAQ:BIOC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biocept (NASDAQ:BIOC)
Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 2.84%
Insider Trades by Quarter for Biocept (NASDAQ:BIOC)
Institutional Ownership by Quarter for Biocept (NASDAQ:BIOC)
Insider Trades by Quarter for Biocept (NASDAQ:BIOC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2016Claire ReissMajor ShareholderBuy227,272$1.10$249,999.20View SEC Filing  
10/19/2016David F. HaleDirectorBuy90,909$1.10$99,999.90View SEC Filing  
10/19/2016Lyle J. ArnoldSVPBuy45,000$1.10$49,500.00View SEC Filing  
10/19/2016Timothy KennedyCFOBuy36,363$1.10$39,999.30View SEC Filing  
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.00View SEC Filing  
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biocept (NASDAQ:BIOC)
Latest Headlines for Biocept (NASDAQ:BIOC)
Source:
DateHeadline
streetinsider.com logoBiocept (BIOC) Awarded U.S. Patent with Broad Claims for Antibody Capture
www.streetinsider.com - May 22 at 11:29 AM
finance.yahoo.com logoBiocept Awarded U.S. Patent with Broad Claims for Antibody Capture of Targets of Interest on Any Solid Surface Including CTCs and Other Materials Shed by Solid Tumors into Blood
finance.yahoo.com - May 22 at 11:29 AM
streetinsider.com logoBiocept (BIOC) Highlights Target Selector Platform in 3 Clinical Abstracts; Plans to Launch New Marketing Campaign
www.streetinsider.com - May 19 at 9:11 AM
finance.yahoo.com logoBiocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society of Clinical Oncology Annual Meeting Where Company Plans to Launch New Marketing Campaign
finance.yahoo.com - May 18 at 3:51 PM
prnewswire.com logoBiocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society of Clinical ... - PR Newswire (press release)
www.prnewswire.com - May 18 at 11:42 AM
finance.yahoo.com logoVaccine may cut HPV infections, an oral cancer risk, in men
finance.yahoo.com - May 17 at 8:59 PM
americanbankingnews.com logoBiocept Inc (BIOC) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 16 at 5:16 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Biocept and Hornbeck Offshore Services
finance.yahoo.com - May 15 at 9:31 AM
prnewswire.com logoThe Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of - PR Newswire (press release)
www.prnewswire.com - May 12 at 4:30 PM
prnewswire.com logoBiocept Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 12 at 4:30 PM
finance.yahoo.com logoETFs with exposure to Biocept, Inc. : May 12, 2017
finance.yahoo.com - May 12 at 4:30 PM
reuters.com logoBRIEF-Biocept reports Q1 loss per share $0.21
www.reuters.com - May 12 at 2:31 AM
finance.yahoo.com logoInvestor Network: Biocept, Inc. to Host Earnings Call
finance.yahoo.com - May 11 at 4:28 PM
finance.yahoo.com logoBiocept Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 4:28 PM
streetinsider.com logoBiocept (BIOC), ALCMI Announce Collaboration and Initiation of ALCMI-009 Liquid Biopsy Clinical Trial in Lung Cancer - StreetInsider.com
www.streetinsider.com - May 10 at 4:09 PM
finance.yahoo.com logoThe Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of Landmark ALCMI-009 Liquid Biopsy Clinical Trial in Lung Cancer
finance.yahoo.com - May 10 at 8:47 AM
americanbankingnews.com logoBiocept Inc (BIOC) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 4:38 PM
americanbankingnews.com logoBiocept Inc (BIOC) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - May 9 at 7:02 AM
americanbankingnews.com logoFavorable Press Coverage Very Unlikely to Impact Biocept (BIOC) Share Price
www.americanbankingnews.com - May 4 at 1:01 AM
finance.yahoo.com logoBiocept to Release First Quarter 2017 Financial Results and Host Investor Conference Call on May 11, 2017 - Yahoo Finance
finance.yahoo.com - May 3 at 1:13 PM
finance.yahoo.com logoBiocept to Release First Quarter 2017 Financial Results and Host Investor Conference Call on May 11, 2017
finance.yahoo.com - May 3 at 1:13 PM
americanbankingnews.com logoBiocept Inc (BIOC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 1 at 8:16 PM
finance.yahoo.com logoETFs with exposure to Biocept, Inc. : May 1, 2017
finance.yahoo.com - May 1 at 3:53 PM
americanbankingnews.com logoBiocept (BIOC) Earning Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 30 at 3:27 PM
americanbankingnews.com logo$1.56 Million in Sales Expected for Biocept Inc (BIOC) This Quarter
www.americanbankingnews.com - April 28 at 2:52 PM
americanbankingnews.com logoBiocept (BIOC) Getting Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 27 at 8:06 PM
americanbankingnews.com logoZacks: Analysts Anticipate Biocept Inc (BIOC) to Post -$0.20 Earnings Per Share
www.americanbankingnews.com - April 26 at 8:50 PM
americanbankingnews.com logoBiocept (BIOC) Given Coverage Optimism Score of 0.20
www.americanbankingnews.com - April 21 at 12:28 PM
finance.yahoo.com logoETFs with exposure to Biocept, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 4:02 PM
reuters.com logoBRIEF-Biocept awarded additional patent in Japan
www.reuters.com - April 19 at 12:38 PM
finance.yahoo.com logoBiocept Awarded Additional Patent in Japan Expanding Intellectual Property Estate to 19 Issued Patents Protecting Its Target Selector™ Liquid Biopsy Platform
finance.yahoo.com - April 18 at 12:47 PM
americanbankingnews.com logoBiocept (BIOC) Receiving Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - April 18 at 8:54 AM
americanbankingnews.com logoShort Interest in Biocept Inc (BIOC) Declines By 1.6%
www.americanbankingnews.com - April 17 at 12:06 PM
americanbankingnews.com logoBiocept (BIOC) Earns Media Sentiment Score of 0.29
www.americanbankingnews.com - April 15 at 11:21 AM
prnewswire.com logoMedical Laboratories Stocks Under Scanner -- Biocept, Exact Sciences, and HTG Molecular Diagnostics
www.prnewswire.com - April 11 at 7:22 AM
finance.yahoo.com logoFDA pick faces questioning on ties to industry he'd regulate
finance.yahoo.com - April 7 at 8:29 AM
finance.yahoo.com logoETFs with exposure to Biocept, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:28 AM
americanbankingnews.com logo-$0.20 Earnings Per Share Expected for Biocept Inc (BIOC) This Quarter
www.americanbankingnews.com - April 5 at 6:04 PM
reuters.com logoBRIEF-Biocept announces collaboration with the OHSU Knight Cancer Institute
www.reuters.com - April 4 at 2:19 AM
finance.yahoo.com logoBiocept Announces Collaboration with the OHSU Knight Cancer Institute to Increase Clinical Adoption of Liquid Biopsy Testing and to Co-Develop Additional Assay Platform Capabilities
finance.yahoo.com - April 3 at 4:19 PM
finance.yahoo.com logoBiocept to Present at The MicroCap Conference on April 4th in New York City
finance.yahoo.com - March 31 at 4:03 PM
finance.yahoo.com logoBIOCEPT INC Financials
finance.yahoo.com - March 31 at 4:03 PM
biz.yahoo.com logoBIOCEPT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, O
biz.yahoo.com - March 30 at 4:19 PM
finance.yahoo.com logoBiocept Announces Pricing of $9.3 Million Financing - Yahoo Finance - Yahoo Finance
finance.yahoo.com - March 29 at 9:16 PM
streetinsider.com logoForm 10-K BIOCEPT INC For: Dec 31
www.streetinsider.com - March 28 at 1:07 PM
biz.yahoo.com logoBIOCEPT INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 28 at 1:07 PM
us.rd.yahoo.com logoBiocept Announces Pricing of $9.3 Million Financing
us.rd.yahoo.com - March 28 at 1:07 PM
us.rd.yahoo.com logo9:11 am Biocept enters into securities purchase agreements with certain institutional investors providing for the purchase and sale of 4,320,000 shares of common stock at a price of $2.15/share and warrants to purchase up to 2,160,000 share
us.rd.yahoo.com - March 28 at 1:07 PM
finance.yahoo.com logoBiocept and OvaScience Post Gains Amid Investor Speculation
finance.yahoo.com - March 23 at 4:20 PM
biz.yahoo.com logoBIOCEPT INC Files SEC form 8-K, Shareholder Director Nominations
biz.yahoo.com - March 23 at 4:20 PM

Social

Biocept (BIOC) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff